NextCure, Inc. (NXTC) vs TScan Therapeutics, Inc. (TCRX)

NextCure, Inc. and TScan Therapeutics, Inc. are both Biotechnology companies. NextCure, Inc. and TScan Therapeutics, Inc. are of similar size ($25.4M and $23.7M). NextCure, Inc. has the higher net margin (0.00% vs −1,655.4%) and the higher return on invested capital (0.00% vs −4,588.2%). Across the 16 metrics below, NextCure, Inc. leads on 11 and TScan Therapeutics, Inc. on 5.

Valuation

Metric NXTC TCRX Biotechnology median
P/E n/m n/m 7.88
P/S 0.99 6.21 11.47
P/B 2.22 0.64 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.20 0.74
EV/Sales 0.49 (3.26) 10.73
Earnings yield (171.26%) (267.65%) (28.84%)
Free cash flow yield (138.87%) (268.00%) (23.03%)

Profitability

Metric NXTC TCRX Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (1,695.15%) 0.00%
Net margin 0.00% (1,655.35%) 0.00%
Free cash flow margin 0.00% (1,665.18%) 0.00%
Return on equity (195.22%) (95.80%) (57.72%)
Return on assets (121.60%) (50.09%) (49.22%)
Return on invested capital 0.00% (4,588.23%) 0.00%

Growth

Metric NXTC TCRX Biotechnology median
Revenue growth (TTM) — 2.15% 5.64%
EPS growth (last fiscal year) 17.75% 12.28% —
Revenue growth, 5-year CAGR — 56.92% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NXTC TCRX Biotechnology median
Debt to equity 0.00 0.47 0.00
Current ratio 3.47 3.37 4.73
Net debt to EBITDA 0.75 0.90 0.96

Dividend

Metric NXTC TCRX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric NXTC TCRX Biotechnology median
Market cap 25.36m 23.65m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack